New Childhood Cancer Drug Approved in 2020
So, in my absence from this blog, something very exciting happened: a new pediatric-specific childhood cancer drug was approved! This happened in April 2020, so semi-recently. The drug is called selumetinib and is primarily for neurofibromatosis, but also used for thyroid cancer, Hodgkin lymphoma, neuroblastoma, acute myeloid leukemia (AML), epithelioid sarcoma, and tumor mutational burden (TMB)–high solid tumors.
The article on an oncology website can be found here, summarizing recent developments in childhood cancer treatments. Read a summary about selumetinib here (Wikipedia).
Comments
Post a Comment